AIM ImmunoTech Spotlights Growing Attention Around Ampligen® Pancreatic Cancer Strategy as DURIPANC Advances Toward Topline Data
Recent biotech media features focus on Ampligen’s potential to address immune resistance in metastatic pancreatic cancer and the clinical progress of the Phase 2 DURIPANC program Recent biotech media features focus on Ampligen’s potential to address immune resistance in metastatic pancreatic cancer and the clinical progress of the Phase 2 DURIPANC program